Cookies on this site

What's new

Under-40s diagnosed with type 2 diabetes have a mortality rate four times higher than the general population

People diagnosed with type 2 diabetes before 40 years of age, have nearly four times the risk of death compared with the general UK population, a new study carried out at the University of Oxford’s Radcliffe Department of Medicine has found.

Hydroxychloroquine provides moderate COVID-19 prevention

COPCOV, the world’s largest COVID-19 chemoprevention study, published results today showing that hydroxychloroquine (HCQ) has a moderate benefit in preventing COVID-19. The COPCOV trial was led globally by the Mahidol Oxford Tropical Medicine Research Unit (MORU), Thailand. The Diabetes Trials Unit (DTU) was the UK coordinating centre for the trial, helped develop the protocol, and was responsible for managing UK sites, approvals and procedures.

Patients receiving steroids are more than twice as likely to develop diabetes, UK study has found

Patients who are being treated with systemic glucocorticoids are more than twice as likely to develop diabetes as those not receiving the treatment, a new study by researchers at the Radcliffe Department of Medicine’s Diabetes Trial Unit has found.

Early blood glucose control for people with type 2 diabetes is crucial for reducing complications and prolonging life

Research led by scientists from the Universities of Oxford and Edinburgh has found that early good blood glucose control can minimise the lifetime risk of diabetes-related complications, including heart attacks, kidney failure and vision loss.

The LEGEND-D Trial – which aims to prevent low blood sugar levels in type 1 diabetes – is open to recruitment

The first participant has completed initial study activities and is now randomised to one of the trial’s arms.

Latest publications

Real-world evidence for decisions in diabetes.

Journal article

Misra S. et al, (2026), Diabetologia

Real-World Databases in Diabetes: A Systematic Review.

Journal article

Thomas JJC. et al, (2026), Diabetes Metab Res Rev, 42

SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population-Based Cross-Sectional Study of Uptake of NICE Guidance.

Journal article

Muller P. et al, (2026), Diabetes Obes Metab, 28, 9573 - 9583